Dermata Therapeutics Warrant Stock Revenue
| DRMAW Stock | USD 0.02 0.0001 0.52% |
Dermata Therapeutics Warrant fundamentals help investors to digest information that contributes to Dermata Therapeutics' financial success or failures. It also enables traders to predict the movement of Dermata Stock. The fundamental analysis module provides a way to measure Dermata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dermata Therapeutics stock.
| Last Reported | Projected for Next Year |
Dermata | Revenue |
Dermata Therapeutics Warrant Company Revenue Analysis
Dermata Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Dermata
Projected quarterly revenue analysis of Dermata Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Dermata Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Dermata Therapeutics' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Dermata Therapeutics Warrant reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Dermata Therapeutics Warrant is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 973,118. Dermata Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.Dermata Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dermata Therapeutics from analyzing Dermata Therapeutics' financial statements. These drivers represent accounts that assess Dermata Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dermata Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 651.4M | 206.6M | 61.6M | (3.2B) | (3.6B) | (3.5B) |
Dermata Fundamentals
| Return On Equity | -2.02 | ||||
| Return On Asset | -1.03 | ||||
| Number Of Shares Shorted | 28.04 K | ||||
| EBITDA | (12.51 B) | ||||
| Net Income | (12.29 B) | ||||
| Total Debt | 1.97 B | ||||
| Book Value Per Share | 2.83 X | ||||
| Cash Flow From Operations | (11.16 B) | ||||
| Earnings Per Share | (2.16) X | ||||
| Beta | 0.65 | ||||
| Total Asset | 3.53 B | ||||
| Retained Earnings | (65.68 B) | ||||
| Working Capital | 6.36 M | ||||
| Net Asset | 3.53 B |
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.